Emcure Pharmaceuticals’ arm inks in-licensing agreement with WiQo

02 Apr 2025 Evaluate

Emcure Pharmaceuticals’ a wholly owned subsidiary -- Emcutix Biopharmaceuticals has signed exclusive in-licensing agreement with WiQo. The strategic partnership grants Emcutix the rights to import, promote, distribute and sell WiQo's product PRX-PLUS in India. The collaboration is set to redefine the landscape of non-invasive skin treatments in the region. 

PRX-PLUS has a unique product feature with its deep-impacting formula that instantly tightens the skin, offering a non-invasive, pain-free alternative to traditional aesthetic treatments for those seeking effective results with convenience. Over 40,000 dermatologists and aesthetic doctors worldwide use WiQo’s patented formulas. Since 2011 over 8 million needle-free skin booster professional procedures have been performed globally. 

Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.

Emcure Pharma Share Price

1395.15 -9.10 (-0.65%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×